Rare coding variants in CHRNB2 reduce the likelihood of smoking
EMBERSON J. et al, (2023), Nature Genetics
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
HERRINGTON W. et al, (2023), Kidney International Reports
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Horby PW. et al, (2023)
Diabetes and infectious disease mortality in Mexico City.
Bragg F. et al, (2023), BMJ Open Diabetes Res Care, 11
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.
Zhou J. et al, (2023), Pharmacoeconomics
Mechanisms and Predictors of Acute Kidney Injury with Perioperative Rosuvastatin in Patients Undergoing Cardiac Surgery
Wijesurendra RS. et al, (2023)
Body Composition and Risk of Vascular-Metabolic Mortality Risk in 113 000 Mexican Men and Women Without Prior Chronic Disease.
Gnatiuc Friedrichs L. et al, (2023), J Am Heart Assoc
Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry.
Lopes LR. et al, (2022), European heart journal. Quality of care & clinical outcomes, 9, 42 - 53
Socioeconomic variations determine the clinical presentation, aetiology, and outcome of infective endocarditis: a prospective cohort study from the ESC-EORP EURO-ENDO (European Infective Endocarditis) registry.
Sengupta SP. et al, (2022), European heart journal. Quality of care & clinical outcomes, 9, 85 - 96
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801
Human genetics uncovers MAP3K15 as an obesity-independent therapeutic target for diabetes.
Nag A. et al, (2022), Sci Adv, 8
Adiposity and NMR-measured lipid and metabolic biomarkers among 30,000 Mexican adults.
Aguilar-Ramirez D. et al, (2022), Commun Med (Lond), 2
Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2022), N Engl J Med
Educational inequalities and premature mortality: the Cuba Prospective Study.
Ross S. et al, (2022), Lancet Public Health, 7, e923 - e931
Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19.
Sandercock PAG. et al, (2022), Trials, 23
Association Between Smoking, Smoking Cessation, and Mortality by Race, Ethnicity, and Sex Among US Adults.
Thomson B. et al, (2022), JAMA Netw Open, 5
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845
Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology.
Staplin N. et al, (2022), Hypertension
Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.
Pitcher A. et al, (2022), Lancet
Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes.
Akbari P. et al, (2022), Nat Commun, 13